Nectar RHS Komplementar ApS: Financial statements 2023
CVR: 41934530
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Nectar RHS Komplementar ApS (CVR 41934530) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,000 and a net result of DKK 15,307 compared with DKK 9,585 the year before. Equity in the 2023 report amounted to DKK 80,492. The solvency ratio was 78.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -5,000
- Profit/Loss
- DKK 15,307
- Equity
- DKK 80,492
- Total Assets
- DKK 102,500
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -5 t. | 15 t. | 80 t. | 1 |
| 2022 | - | -13 t. | 10 t. | 65 t. | 0 |
| 2021 | - | -5 t. | 16 t. | 56 t. | 0 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Nectar RHS Komplementar ApS has published its annual report for 2022. Gross profit came to DKK -12,500, and the net result was DKK 9,585.
About Nectar RHS Komplementar ApS
Nectar RHS Komplementar ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Bjørk Krogshave. The company is owned by PharmaService I/S and Nectar Invest A/S. In 2025, the company reported a gross profit of DKK -5,000 and a net result of DKK 38,849 compared with DKK 58,075 the year before. Equity in the 2025 report amounted to DKK 177,416.